🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the pathogen, according to health experts.

An International Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting more than 82 million infections per year. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce therapeutic options presently on offer.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This approval represents a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Data and Global Access

As per results released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of cases of the STI. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The research enrolled nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed optimism. Access to a easy-to-administer therapy such as this is seen as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the disease for individuals and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.